HER2-NEGATIVE GASTRIC ADENOCARCINOMA
Clinical trials for HER2-NEGATIVE GASTRIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HER2-NEGATIVE GASTRIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for HER2-NEGATIVE GASTRIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Hard-to-Treat cancers in large trial
Disease control Recruiting nowThis phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…
Matched conditions: HER2-NEGATIVE GASTRIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New cocktail aims to shrink stomach tumors before surgery
Disease control Recruiting nowThis phase 2 trial tests whether adding radiotherapy and two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy can improve outcomes for people with resectable stomach or gastroesophageal junction cancer. About 40 participants will be randomly assigned to…
Matched conditions: HER2-NEGATIVE GASTRIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University • Aim: Disease control
Last updated Jun 26, 2026 16:10 UTC